BrainStorm Cell Therapeutics announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). NurOwn is a mesenchymal stem cell (MSC) platform created for the treatment of ALS. Because it is made from MSCs,…
Participating in the 2017 Annual Northeast ALS Consortium (NEALS) meeting in Florida recently, biotech company Oxford BioDynamics presented two different epigenetic signatures for the diagnosis and prognosis of amyotrophic lateral sclerosis (ALS). The presentation was a result of a prospective study to determine the sensitivity and specificity of two…
Pete Frates, the Boston man who invented the Ice Bucket Challenge that raised millions for ALS, was reported to have kicked the bucket this summer — but it turned out to be a newspaper’s goof. The erroneous report stemmed from a headline in Britain’s Sun declaring that the 32-year-old had died…
The company Verge Genomics, which uses genomic data for neuroscience therapeutics, announced that it will join specialized departments at four top universities to boost research in amyotrophic lateral sclerosis (ALS). The innovative industry-academic collaboration will combine machine learning with genomic, genetic, biological, and phenotypical data to accelerate the translation…
Neuroscientist and professor Niels Birbaumer, a senior research fellow at Switzerland’s Wyss Center in Geneva, has written a new book investigating the brain’s seemingly limitless capacity  to reshape itself and overcome disease. Birbaumer has conducted research with amyotrophic lateral sclerosis (ALS) patients who, because of their progressive motor neuron disease, have…
The National Institutes of Health has awarded $30 million over two years to 13 researchers who are developing three-dimensional models of amyotrophic lateral sclerosis and other diseases. Researchers say the initiative is aimed at tackling a translational science problem: More than 60 percent of therapies prove ineffective in clinical trials of…
Project ALS and Amylyx Pharmaceuticals will collaborate on preclinical studies of Amylyx’s lead compound AMX0035 as a potential treatment for patients with amyotrophic lateral sclerosis (ALS). These studies will complement Amylyx’s recently initiated Phase 2 CENTAUR clinical trial (NCT03127514), which will evaluate AMX0035 in 132 patients. Since mitochondrial…
The ALS Association of Georgia has received a $10,000 donation from William Mills Agency (WMA), an independent public relations and content marketing firm, to help the non-profit fund research and services to the local amyotrophic lateral sclerosis (ALS) community. William Mills lost its founder, William ‘Bill’ Mills Jr.,…
Option Care Enterprises will become a national provider of home infusion services for Radicava (edaravone), the first treatment for amyotrophic lateral sclerosis that the United States has approved in more than 20 years. Bannockburn, Illinois-based Option Care will provide the services under an agreement with Mitsubishi Tanabe Pharma America,…
The Boston prep school that ALS patient Pete Frates attended has recognized him for creating the Ice Bucket Challenge that has generated a tidal wave of funding for research on the disease. St. John’s Prep named Frates, who was diagnosed with amyotrophic lateral sclerosis in 2012 at the age of 27,…
Get regular updates to your inbox.